Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03641261
Other study ID # RC31/16/8765
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 29, 2018
Est. completion date February 21, 2023

Study information

Verified date April 2024
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose is to evaluate the feasibility (global use) of a therapeutic patient education program using a specific web application in patients with hereditary ichthyosis.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date February 21, 2023
Est. primary completion date February 21, 2023
Accepts healthy volunteers No
Gender All
Age group 15 Years to 60 Years
Eligibility Inclusion Criteria: - Patient with hereditary ichthyosis, according to the classification established during the 2009 consensus conference - Who has given his informed consent form - Who is affiliated to a social security system Exclusion Criteria: - Patient who has already participated in a therapeutic patient education program for the hereditary ichthyosis - Unable to connect or use a computer tool - Impossibility to be present at the only face-to-face session - Patient who is not available for the collective educational session - Patient with little or no motivation to follow a therapeutic patient education program (motivation evaluated by the educational team by phone call before inclusion) - Patient not mastering the French language - Person under legal protection (guardianship, curators or safeguard of justice)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Therapeutic patient education program
WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team

Locations

Country Name City State
France CHU Toulouse, Hôpital Larrey Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Global use percentage of patients who have used the "WebIchtyose" application for at least 8 hours during 6 months 6 months
Secondary Fractional use in each domain (educational sessions) "WebIchtyose" application use time by the patient for group and individual educational sessions 6 months
Secondary Fractional use in each domain (continuous educational follow-up) "WebIchtyose" application use time by the patient for the continuous educational follow-up 6 months
Secondary Fractional use in each domain (consultation) "WebIchtyose" application use time by the patient for the consultation of the "Frequently Asked Questions" area and of patient information documents made available on the application 6 months
Secondary Fractional use in each domain (questionnaires) "WebIchtyose" application use time by the patient for the filling of the questionnaires 6 months
Secondary Fractional use in each domain "WebIchtyose" application use time by the patient for group and individual educational sessions, the continuous educational follow-up, the consultation of the "Frequently Asked Questions" area and of patient information documents made available on the application 6 months
Secondary Difficulty of individual application registration Difficulty of registration questionnaire completed for each patient jointly by the patient and the educational team at the end of the face-to-face inclusion visit Baseline
Secondary Difficulties of use in everyday life by the patient Questionnaire completed for each patient jointly by the patient at the end of the program 6 months
Secondary Number of exchanges Number of exchanges necessary between the educational team and the patient to set a date for the conduct of the individual educational sessions 3 months and 5 months
Secondary Response time Response time of the educational team following a request from the patient as part of the educational follow-up 6 months
Secondary Number of relaunches How many times the nurse relaunches the patient to obtain the assessment questionnaires 2 months, 4 months and 6 months
Secondary Number of non-received questionnaires Number of non-received questionnaires after relaunch 2 months, 4 months and 6 months
Secondary Number of lost to follow-up patients Number of lost to follow-up patients 9 months
Secondary Patient acceptability Acceptability questionnaire to be completed by the patient 6 months
Secondary Educational team acceptability Acceptability questionnaire to be completed by each member of the educational team 6 months
Secondary Attractiveness Application attractiveness questionnaire completed by the patient 6 months
Secondary Quality of life before and after treatment Quality of life questionnaire for hereditary ichthyosis (IQoL-32) Inclusion, 6 months and 9 months
Secondary Self-assessment of cutaneous severity Self-assessment of cutaneous severity according to an analogic visual scale for pain, pruritus, erythema, squama Inclusion and 6 months
Secondary Knowledge about disease and treatments Questionnaire of knowledge about disease and treatments Inclusion and 6 months
Secondary Self-care skills Questionnaire of self-care skills Inclusion and 6 months
Secondary Self-esteem Questionnaire about self-esteem: Rosenberg scale. For each item of the questionnaire, the modality answers are : 1 (totally disagree), 2 (quite disagree), 3 (quite agree) and 4 (totally disagree). The total score (/ 40) is calculated by adding the scores obtained for each item. Inclusion and 6 months
Secondary Coping scale Coping with health injuries and problem (Endler 1998). For each item of the questionnaire, the modality answers are: 1 (not at all), 2 (a little), 3 (moderately), 4 (often) and 5 (a lot).The total score (/ 160) is calculated by adding the scores obtained for each item. Inclusion and 6 months
See also
  Status Clinical Trial Phase
Completed NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT00004690 - Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis Phase 3
Completed NCT00074685 - National Registry for Ichthyosis and Related Disorders
Completed NCT03796052 - Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients N/A
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Active, not recruiting NCT05295732 - The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis Phase 3
Terminated NCT02655861 - A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
Recruiting NCT03464994 - Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO) N/A
Recruiting NCT03417856 - Defining the Skin and Blood Biomarkers of Ichthyosis
Terminated NCT04697056 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Phase 2
Recruiting NCT06330350 - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases
Completed NCT03041038 - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Phase 2
Not yet recruiting NCT06362447 - Efficacy of Injectable Gentamicin in Hereditary Ichthyosis Phase 2
Active, not recruiting NCT04549792 - An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses Early Phase 1